查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837442

疟疾疫苗市场按疫苗类型、最终用户、给药途径、年龄层和剂量方案划分－2025-2032年全球预测

Malaria Vaccine Market by Vaccine Type, End User, Route Of Administration, Age Group, Dosage Schedule - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，疟疾疫苗市场规模将达到 5.3096 亿美元，复合年增长率为 26.51%。

主要市场统计数据
基准年 2024 8088万美元
预计年份：2025年 1.0259亿美元
预测年份：2032年 5.3096亿美元
复合年增长率 (%) 26.51%

一个权威的疟疾疫苗领域框架，将科学突破与政策路径和实施现实联繫起来，以支持实际决策。

全球疟疾疫苗研发的讨论正从充满希望的实验转向有计划的研发，这主要得益于免疫学的进步、新型平台技术的出现以及政策重点的转变。近期临床试验的成功检验，而实际的免疫接种计画也日益重视评估如何将这些疫苗整合到现有的公共卫生体系中。随着包括研究机构、政府机构、非政府组织和私营部门在内的相关人员审查疫情应对策略，简洁明了、基于证据且全面的资讯对于做出明智的决策至关重要。

本报告旨在清晰、客观、以行动为导向地分析疟疾疫苗推广应用的科学发展轨迹、发展挑战以及相关人员的奖励。报告透过分析监管动态、给药途径、终端用户回馈以及不同年龄层的疫苗接种策略，将实验室突破与实际操作联繫起来。最终，本报告旨在为领导者提供必要的背景信息，以便他们优先考虑投资、设计试验计画，并协调合作伙伴，共同实现永续、可衡量的公共卫生成果。

平台创新、监管加速和供应链现代化如何重新定义疫苗选择、部署策略和专案可行性

疟疾疫苗领域正经历一场变革时期，其特点是平台多样化、监管法规不断演变以及部署理念日趋完善。 mRNA和病毒载体平台正从实验阶段迈向临床应用阶段，而蛋白质次单元和结合製剂则持续展现出符合免疫规划要求的安全性。同时，适应性测试设计和快速的监管行动缩短了从证据产生到政策制定的时间，从而能够更快地将疗效数据转化为流行地区的实验室应用。

同时，供应链和製造领域的创新正在重塑疫苗规模化生产的格局。低温运输解决方案、冷冻干燥技术和分散式生产模式的进步，正在缓解过去限制疫苗普及的种种限制因素。资金筹措机制和官民合作关係也在不断发展，以承担疫苗部署的初期成本。总而言之，这些转变预示着一个新时代的到来：疫苗的选择不仅取决于其有效性，还将考虑物流、成本效益以及与不同卫生系统之间的兼容性。

了解不断变化的关税政策如何改变疟疾疫苗供应链中的筹资策略、采购动态和本地製造优先事项

主要经济体贸易和关税调整引发的政策转变正对全球医疗保健供应链产生复杂的影响，尤其对疫苗采购和分发计画具有特殊意义。关税结构的变化会改变关键投入品和成品疫苗的到岸成本，影响生产地点的选择，并改变供应商和买家之间的谈判动态。对于疟疾疫苗而言，其供应链可能包含多个环节，例如mRNA专用脂质、病毒载体生产试剂以及填充和包装服务，因此关税差异可能对筹资策略和交货时间产生重大影响。

此外，关税调整可能会促使製造商和采购负责人寻求对冲政策风险，从而推动策略供应商多元化。在某些情况下，关税相关的考量可能会加速某些生产活动在地化的奖励，促进区域製造地的形成，从而降低跨境贸易摩擦的风险。此类发展也可能影响国际捐助者和国家疫苗接种计画所使用的采购工具，迫使它们重新调整竞标规范和合约条款，以维持疫苗的可负担性和可预测性。总而言之，关税波动提醒我们，宏观经济政策可能会对疫苗供应和推广计画等营运决策产生连锁反应。

一个细緻的细分框架，将疫苗平台、最终用户角色、给药途径、年龄层和接种方案与计画契合度和策略重点连结起来。

将疟疾疫苗市场细分，可以发现不同的需求和决策标准，这些因素直接影响产品开发的优先顺序和专案的实施。依疫苗类型划分，市场包括结合疫苗、活病毒疫苗、mRNA疫苗、次单位疫苗和病毒载体疫苗。 mRNA疫苗市场进一步分为传统mRNA疫苗及自扩增mRNA疫苗，病毒载体疫苗则分为腺病毒载体及MVA载体平台。按最终用户划分，该生态系统涵盖非政府组织、私人诊所和公共免疫项目，其中公共免疫项目进一步细分为区域项目和国家项目。依给药途径划分，肌肉注射、口服和皮下注射对第一线医护人员的训练、遵从性和废弃物管理的影响各不相同。按年龄组别划分，青少年和成人、儿童和婴儿需要进行客製化的临床评估和计画设计，其中儿童群体进一步细分为学龄前儿童和学龄儿童，这反映了不同的给药平台和知情同意机制。根据给药方案的不同，单剂量、三剂量和两剂量方案对后续系统、依从性策略和成本计划造成了不同的后勤负担。

整合这些细分维度表明，产品选择不能孤立地进行。例如，一种剂量节省、可自我扩增的mRNA候选药物可能对旨在最大限度减少低温运输压力的国家计画极具吸引力，但其生产规模和监管成熟度可能会对地方试验计画或个别诊所构成障碍。同样，一种简化婴幼儿用药的口服製剂可能对推广宣传活动产生变革性影响。同时，一种具有强大依从性支持的三剂次次单元给药方案可能非常适合学龄前儿童和学龄儿童的校内给药。认识到这些跨细分领域的依赖性，有助于相关人员优先考虑投资组合，设计合适的给药模式，并将临床开发策略与目标最终使用者的实际情况相协调。

区域间监管准备、生产能力和供应基础设施的差异将决定疫苗部署和规模化的方法。

医疗基础设施、监管管道和资金筹措模式的区域差异造成了不同的推广应用场景，这些都必须在策略规划中加以考虑。在美洲，完善的监管机构和公私混合的医疗服务体係有利于都市区率先推广，私人诊所和慈善机构通常会主导有针对性的试验计画。虽然该地区的供应链网路能够满足复杂配方的需求，但偏远和农村地区仍面临配送挑战，因此需要低温运输创新和社区参与策略。

欧洲、中东和非洲的实际情况各不相同。一些欧洲市场正在推动监管协调，而中东和非洲部分地区则面临基础设施的限制。在非洲，国家疫苗接种计画在疫苗推广计画中扮演越来越重要的角色，区域间的生产和采购合作也日益受到重视，以减少对远距离供应商的依赖。同时，中东地区为区域製造和物流中心提供了服务邻近流行市场的机会，但前提是需要对当地产能进行投资并协调监管。

在亚太地区，存在着多种因素，包括生产能力、先进的公共疫苗接种基础设施以及大规模疫苗外交能力。虽然东南亚和南亚部分地区人口稠密有利于疫苗的推广，但不同的监管时间表和资金筹措机制需要製定量身定制的参与策略。在所有地区，社区参与、卫生工作者培训以及将疫苗纳入现有常规免疫计划仍然是成功实施的关键。

开发商、製造商、物流商和专案合作伙伴之间的跨部门合作如何影响候选方案的可行性和采用管道

领先的生物製药和生物技术公司、学术联盟以及专业合约服务供应商正在塑造疟疾疫苗的研发和推广过程。临床开发人员正在推动各种平台技术的研发，而关于製剂稳定性、低温运输要求和给药方案的策略选择将影响专案合作伙伴对试验性产品的接受程度。契约製造製造商和填充包装专家正在调整生产能力，以满足从小批量临床用药到大批量计划用药的各种需求，而物流供应商则在温控运输和最后一公里配送方面进行创新。

伙伴关係模式正变得更加重视交易而非策略，授权协议、联合开发伙伴关係和技术转移安排正在加速提升本地生产能力。非营利组织和多边倡议仍然是重要的召集者，它们促进数据共用、早期资金筹措和示范计划的营运支援。这些相关人员共同建构了一个生态系统，在这个生态系统中，监管要求、品质保证和真实世界证据的一致性将决定哪些候选疫苗能够从临床实验试验阶段进入常规应用阶段。

为平衡短期实施需求与长期创新和韧性供应链策略，提出切实可行的方案建议。

产业领导者应采取务实的、以投资组合为导向的方法，在短期可行性和长期技术投入之间取得平衡。他们优先投资于能够融入现有免疫基础设施的候选疫苗，尤其是那些稳定性好、给药途径简便的疫苗，同时也支持那些能够减少疫苗剂量并具有广泛免疫抗原性的创新平台。同时，他们正在加快与区域製造商和合约服务供应商的合作，以避免贸易和供应链风险，并缩短向流行地区交付疫苗的前置作业时间。

在研发初期，我们正加强与官方免疫机构、地方专案管理人员和当地相关人员的合作，以确保专案限制因素能够体现在测试设计和引入后评估中。我们正在投资于针对不同年龄层的接种方案和接种点量身定制的人员培训、低温运输优化以及依从性支援机制。最后，我们正在建立一个灵活的采购框架，以适应多种产品类型和接种方案，从而能够随着新的临床证据和监管指南的出现而快速调整。实施这些建议将有助于提高疟疾疫苗在不同环境下的引入速度和永续性。

采用透明、以证据主导的方法，结合专家同侪审查的科学研究、监管讯号和营运洞察，使临床特征与专案实际情况相符。

本分析整合了一手和二手证据，建构了疟疾疫苗现况的多面观点。研究方法结合了对同行评审期刊、监管指导文件和临床试验註册库的文献综述，以及针对疫苗学、供应链管理和公共卫生计画实施等领域专家的结构化咨询。此外，还审查了现有免疫项目的实施后评估和营运报告（如有），以总结物流、依从性和社区接受度的经验教训。

本研究采用资料三角测量法来协调资讯来源之间的差异，并着重于检验的政策声明、已发表的临床终点以及已记录的实施经验。调查方法优先考虑资讯来源选择的透明度和假设的记录，分析框架将产品属性与专案限制清晰地连结起来，以确保其具有可操作性。伦理方面的考量包括谨慎解读临床数据，并在证据仍在不断涌现时避免过早提出政策建议。

平衡整合将科学进步与操作需求相结合，为可持续的疟疾疫苗实施提供切实可行的途径。

疟疾疫苗研发的累积趋势是谨慎乐观，但同时也面临操作上的复杂性。科学进步拓宽了可行的疫苗平台选择范围，但成功实施取决于产品特性与最终用户、递送系统和当地供应链的实际情况相符。监管力度和新型资金筹措机制为加快实施提供了机会，但成功的专案需要对低温运输物流、剂量合规性和社区信任度给予高度重视。

展望未来，最有前景的路径在于将务实的近期选择（选择符合现有免疫流程的产品）与对平台技术和本地生产能力的策略性投资相结合。这样做将使决策者能够降低贸易政策、供应中断和卫生系统准备变化带来的风险，同时保留减轻疟疾流行地区负担的潜力。其目标是透过精心设计和永续实施的疫苗策略，将科学进步转化为发病率和死亡率的持续下降。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 恶性疟疾原虫基因变异对非洲和亚洲人群疫苗效力的影响
  • 将RTS,S疫苗纳入国家免疫规划，并加强相关低温运输建设。
  • 针对多种疟疾原虫的新一代多效价疟疾疫苗正在进行临床试验
  • 透过官民合作关係技术倡议加速疫苗生产能力
  • 上市后监测，以评估长期免疫力以及儿童加强免疫接种的必要性
  • 成本效益分析为全球疟疾疫苗资助机构的筹资策略提供资讯

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

8. 依疫苗类型分類的疟疾疫苗市场

  • 结合疫苗
  • 减毒活疫苗
  • mRNA疫苗
    • 常规mRNA
    • 自扩增mRNA
  • 次单位疫苗
  • 病毒载体疫苗
    • 腺病毒载体
    • Mva 向量

9. 按最终用户分類的疟疾疫苗市场

  • NGO
  • 私人诊所
  • 公共疫苗接种计划
    • 区域项目
    • 国家计划

第十章 依给药途径分類的疟疾疫苗市场

  • 肌肉内注射
  • 口服
  • 皮下

第十一章 按年龄组别分類的疟疾疫苗市场

  • 青春期和成年期
  • 幼儿期
    • 幼稚园
    • 学龄
  • 婴儿期

12. 依接种时间表分類的疟疾疫苗市场

  • 1. 接种疫苗
  • 接种疫苗 3 次
  • 两剂疫苗

第十三章 疟疾疫苗市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 疟疾疫苗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国疟疾疫苗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • GlaxoSmithKline plc
    • Serum Institute of India Pvt. Ltd.
    • Bharat BIoTech International Limited
    • Sanofi SA
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Janssen Pharmaceuticals, Inc.
    • Novavax, Inc.
    • BioNTech SE
    • Moderna, Inc.
Product Code: MRR-035DA3C63710

The Malaria Vaccine Market is projected to grow by USD 530.96 million at a CAGR of 26.51% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 80.88 million
Estimated Year [2025] USD 102.59 million
Forecast Year [2032] USD 530.96 million
CAGR (%) 26.51%

An authoritative framing of the malaria vaccine environment that connects scientific breakthroughs to policy pathways and implementation realities for practical decision-making

The global discourse around malaria vaccine development has shifted from hopeful experimentation to deliberate deployment planning, driven by advances in immunology, novel platform technologies, and shifting policy priorities. Recent clinical achievements have validated multiple vaccine approaches, while real-world immunization programs are increasingly prepared to evaluate integration into existing public health architectures. As stakeholders across research institutions, government agencies, non-governmental organizations, and private providers reassess endemic control strategies, a concise, evidence-based synthesis of the landscape becomes indispensable for informed decision-making.

This introduction frames the report's purpose: to present a clear, objective, and practice-oriented examination of scientific trajectories, delivery challenges, and stakeholder incentives shaping malaria vaccine adoption. By grounding the analysis in regulatory developments, route of administration considerations, end-user readiness, and age-specific vaccination strategies, the narrative connects laboratory breakthroughs with implementation realities. Ultimately, the intent is to provide leaders with the context they need to prioritize investments, design pilot programs, and align partners around durable, measurable public health outcomes.

How platform innovation, regulatory acceleration, and supply chain modernization are jointly redefining vaccine selection, deployment strategies, and programmatic feasibility

The malaria vaccine landscape has entered a transformative phase characterized by platform diversification, regulatory evolution, and more sophisticated deployment thinking. mRNA and viral vector platforms have migrated from experimental candidates to clinically relevant contenders, while protein subunit and conjugate formulations continue to offer established safety profiles that appeal to immunization programs. In parallel, adaptive trial designs and accelerated regulatory pathways have reduced latency between evidence generation and policy consideration, enabling faster transitions from efficacy data to pilot implementation in endemic regions.

Concurrently, supply chain and manufacturing innovations are reshaping potential scale-up scenarios. Advances in cold chain solutions, lyophilization approaches, and decentralized manufacturing models are mitigating historical constraints that limited vaccine reach. Financing mechanisms and public-private partnerships are also evolving to underwrite the early costs of introduction, while community engagement strategies have become more sophisticated, reflecting lessons learned from recent mass vaccination efforts. Taken together, these shifts herald a new era in which vaccine choices will be driven not only by efficacy but also by logistics, cost-efficiency, and programmatic fit across diverse health systems.

Understanding how evolving tariff policies reshape sourcing strategies, procurement dynamics, and regional manufacturing priorities for malaria vaccine supply chains

Policy shifts originating from trade and tariff adjustments in leading economies are affecting global health supply chains in complex ways, with tangible implications for vaccine procurement and distribution planning. Changes in tariff structures can alter the landed cost of critical inputs and finished vaccine doses, influence manufacturing site selection, and shift negotiation dynamics between suppliers and procurers. For malaria vaccines, which may rely on multi-component supply chains including specialty lipids for mRNA, viral vector production reagents, and fill-finish services, tariff differentials can meaningfully affect sourcing strategies and time-to-delivery considerations.

Moreover, tariff adjustments can prompt strategic supplier diversification as manufacturers and procurers seek to hedge policy risk. In some cases, incentives to localize certain production activities have been accelerated by tariff-related considerations, promoting regional manufacturing hubs that reduce exposure to cross-border trade frictions. These developments also influence procurement instruments used by international donors and national immunization programs, which may need to recalibrate tender specifications and contract terms to maintain affordability and predictability. In aggregate, tariff changes are a reminder that macroeconomic policy levers can cascade into operational decisions on vaccine availability and rollout timelines.

A nuanced segmentation framework linking vaccine platforms, end-user roles, administration routes, age cohorts, and dosing schedules to programmatic suitability and strategic priorities

Segmenting the malaria vaccine landscape reveals differentiated needs and decision criteria that directly influence product development priorities and programmatic adoption. Based on vaccine type, the market includes conjugate vaccines, live attenuated vaccines, mRNA vaccines, subunit vaccines, and viral vector vaccines, with mRNA further differentiated into conventional mRNA and self-amplifying mRNA, and viral vectors further partitioned into adenovirus vector and MVA vector platforms; each category carries unique manufacturing, stability, and immunogenicity considerations that affect suitability for various settings. Based on end user, the ecosystem spans non-governmental organizations, private clinics, and public immunization programs, with public immunization efforts further divided into local programs and national programs, and each end-user segment exhibits distinct procurement timelines, funding modalities, and cold chain expectations. Based on route of administration, intramuscular, oral, and subcutaneous options present different training, compliance, and waste-management implications for frontline health workers. Based on age group, adolescent and adult cohorts, children, and infants require tailored clinical evaluation and program design, with the child cohort further split into preschool and school-age populations to reflect divergent delivery platforms and consent mechanisms. Based on dosage schedule, single-dose, three-dose, and two-dose regimens impose varying logistical burdens on follow-up systems, adherence strategies, and cost planning.

Integrating these segmentation axes demonstrates that product selection cannot be siloed. For example, a self-amplifying mRNA candidate that promises dose-sparing properties may be attractive for national programs seeking to minimize cold chain strain, but its manufacturing footprint and regulatory maturity may present barriers for local pilot programs or private clinics. Similarly, an oral formulation that simplifies administration for infants could transform outreach campaigns, while a three-dose subunit schedule may align better with school-based delivery for preschool and school-age children if adherence supports are robust. Recognizing these cross-cutting dependencies allows stakeholders to prioritize portfolio investments, design appropriate delivery models, and align clinical development strategies with the operational realities of targeted end users.

Regional distinctions in regulatory readiness, manufacturing capacity, and delivery infrastructure that determine tailored approaches to vaccine introduction and scale-up

Regional variation in health infrastructure, regulatory pathways, and financing models creates divergent adoption scenarios that must be accounted for in strategic planning. In the Americas, established regulatory agencies and mixed public-private delivery landscapes favor early adoption in urban settings, with private clinics and philanthropic initiatives often leading targeted pilot programs. Supply chain networks in the region can support complex formulations, but remote and rural areas still present distribution challenges that require cold chain innovation and community engagement strategies.

Europe, Middle East & Africa encompasses a broad set of realities where robust regulatory harmonization in some European markets contrasts with infrastructure constraints in parts of the Middle East and Africa. National immunization programs in Africa are increasingly central to introduction planning, and regional collaboration on manufacturing and procurement is gaining traction as a means to reduce dependency on distant suppliers. Meanwhile, the Middle East offers opportunities for regional manufacturing and logistics hubs that can serve adjacent endemic markets, contingent on investment in local capacity and regulatory alignment.

Asia-Pacific presents a heterogeneous landscape as well, with several countries demonstrating strong manufacturing capabilities, sophisticated public immunization infrastructures, and capacity for large-scale vaccine diplomacy. In Southeast Asia and parts of South Asia, dense population centers provide implementation advantages, but varied regulatory timelines and financing mechanisms necessitate tailored entry strategies. Across all regions, localized community engagement, training for health workers, and integration with existing routine immunization schedules remain central to successful introduction.

How cross-sector collaboration among developers, manufacturers, logisticians, and program partners is shaping candidate viability and introduction pathways

Leading biopharmaceutical and biotechnology organizations, academic consortia, and specialized contract service providers are all shaping the trajectory of malaria vaccine development and deployment. Clinical developers are advancing diverse platform technologies, and their strategic choices around formulation stability, cold chain requirements, and dosing regimens influence the willingness of programmatic partners to pilot and adopt products. Contract manufacturers and fill-finish specialists are adapting to the demand for flexible capacity that can support both small-scale clinical lots and larger programmatic batches, while logistics providers are innovating around temperature-controlled transport and last-mile delivery.

Partnership models have become more transactional and more strategic at once, with licensing agreements, co-development partnerships, and technology-transfer arrangements accelerating local production capabilities. Nonprofit organizations and multilateral initiatives remain critical conveners, enabling data-sharing, financing for initial introductions, and operational support for demonstration projects. Collectively, these actors are creating an ecosystem in which alignment on regulatory requirements, quality assurance, and real-world evidence generation will determine which vaccine candidates transition from trial settings into routine use.

Practical, program-aligned recommendations for balancing immediate implementation needs with long-term innovation and resilient supply chain strategies

Industry leaders should adopt a pragmatic, portfolio-oriented approach that balances near-term implementability with longer-term technological bets. Prioritize investments in candidates that align with existing immunization infrastructures, particularly those with favorable stability profiles and simple administration routes, while maintaining parallel support for innovative platforms that promise dose-sparing or broader immunogenicity. Concurrently, accelerate partnerships with regional manufacturers and contract service providers to hedge against trade and supply chain risks and to reduce lead times for delivery to endemic settings.

Strengthen engagement with public immunization authorities, local program managers, and community stakeholders early in development to incorporate programmatic constraints into trial design and post-introduction evaluations. Invest in workforce training, cold chain optimization, and adherence-support mechanisms tailored to dosage schedules and age-specific delivery points. Finally, establish flexible procurement frameworks that can accommodate multiple product types and dosing regimens, enabling swift adaptation as new clinical evidence and regulatory guidance emerge. Implementing these recommendations will enhance both the speed and sustainability of malaria vaccine adoption across diverse contexts.

A transparent, evidence-driven methodology combining peer-reviewed science, regulatory signals, and implementation insights to align clinical attributes with programmatic realities

This analysis synthesizes primary and secondary evidence to build a multidimensional view of the malaria vaccine environment. The research approach combined targeted literature review of peer-reviewed journals, regulatory guidance documents, and clinical trial registries with structured expert consultations across vaccinology, supply chain management, and public health program implementation. Where available, post-introduction evaluations and operational reports from existing immunization programs were reviewed to extract lessons on logistics, adherence, and community acceptance.

Data triangulation was used to reconcile differences across sources, and emphasis was placed on verifiable policy statements, published clinical endpoints, and documented implementation experiences. The methodology prioritized transparency in source selection and documented assumptions, and the analytical framework explicitly connected product attributes to programmatic constraints to ensure actionable relevance. Ethical considerations included the careful interpretation of clinical data and the avoidance of premature policy recommendations where evidence remains emergent.

A balanced synthesis that links scientific progress to operational imperatives and outlines the pragmatic paths toward sustainable malaria vaccine implementation

The cumulative picture of malaria vaccine development is one of cautious optimism tempered by operational complexity. Scientific advances have broadened the menu of viable vaccine platforms, but successful introduction will hinge on aligning product characteristics with the realities of end users, delivery systems, and regional supply chains. Regulatory momentum and novel financing structures create opportunities for faster uptake, yet programmatic success will require meticulous attention to cold chain logistics, dosing adherence, and community trust.

Looking ahead, the most promising pathways blend pragmatic short-term choices-favoring products that fit existing immunization workflows-with strategic investments in platform technologies and regional manufacturing capacity. By doing so, decision-makers can mitigate risks associated with trade policy, supply disruptions, and variable health system readiness, while preserving the potential for transformative impact on malaria burden in endemic regions. The objective remains clear: translate scientific progress into durable reductions in morbidity and mortality through thoughtfully designed and sustainably implemented vaccination strategies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Impact of genetic variations of Plasmodium falciparum on vaccine efficacy across African and Asian populations
  • 5.2. Integration of RTS,S vaccine into national immunization schedules and associated cold chain enhancements
  • 5.3. Ongoing clinical trials of next-generation multivalent malaria vaccines targeting multiple Plasmodium species
  • 5.4. Public-private partnerships accelerating vaccine production capacity through technology transfer initiatives
  • 5.5. Real-world post-marketing surveillance assessing long-term immunity and booster dose requirements in children
  • 5.6. Cost-effectiveness analyses shaping procurement strategies among global funding organizations for malaria vaccines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Malaria Vaccine Market, by Vaccine Type

  • 8.1. Conjugate Vaccine
  • 8.2. Live Attenuated Vaccine
  • 8.3. Mrna Vaccine
    • 8.3.1. Conventional Mrna
    • 8.3.2. Self Amplifying Mrna
  • 8.4. Subunit Vaccine
  • 8.5. Viral Vector Vaccine
    • 8.5.1. Adenovirus Vector
    • 8.5.2. Mva Vector

9. Malaria Vaccine Market, by End User

  • 9.1. Ngos
  • 9.2. Private Clinics
  • 9.3. Public Immunization Programs
    • 9.3.1. Local Programs
    • 9.3.2. National Programs

10. Malaria Vaccine Market, by Route Of Administration

  • 10.1. Intramuscular
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Malaria Vaccine Market, by Age Group

  • 11.1. Adolescent & Adult
  • 11.2. Child
    • 11.2.1. Preschool
    • 11.2.2. School Age
  • 11.3. Infant

12. Malaria Vaccine Market, by Dosage Schedule

  • 12.1. Single Dose
  • 12.2. Three Dose
  • 12.3. Two Dose

13. Malaria Vaccine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Malaria Vaccine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Malaria Vaccine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. GlaxoSmithKline plc
    • 16.3.2. Serum Institute of India Pvt. Ltd.
    • 16.3.3. Bharat Biotech International Limited
    • 16.3.4. Sanofi S.A.
    • 16.3.5. Merck & Co., Inc.
    • 16.3.6. Pfizer Inc.
    • 16.3.7. Janssen Pharmaceuticals, Inc.
    • 16.3.8. Novavax, Inc.
    • 16.3.9. BioNTech SE
    • 16.3.10. Moderna, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MALARIA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS MALARIA VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL MALARIA VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. MALARIA VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. MALARIA VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MALARIA VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MALARIA VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MALARIA VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONJUGATE VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MALARIA VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MALARIA VACCINE MARKET SIZE, BY CONVENTIONAL MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MALARIA VACCINE MARKET SIZE, BY SELF AMPLIFYING MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBUNIT VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADENOVIRUS VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MALARIA VACCINE MARKET SIZE, BY MVA VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MALARIA VACCINE MARKET SIZE, BY NGOS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MALARIA VACCINE MARKET SIZE, BY LOCAL PROGRAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MALARIA VACCINE MARKET SIZE, BY NATIONAL PROGRAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MALARIA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MALARIA VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MALARIA VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MALARIA VACCINE MARKET SIZE, BY ADOLESCENT & ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MALARIA VACCINE MARKET SIZE, BY CHILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRESCHOOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MALARIA VACCINE MARKET SIZE, BY SCHOOL AGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MALARIA VACCINE MARKET SIZE, BY INFANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MALARIA VACCINE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MALARIA VACCINE MARKET SIZE, BY THREE DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MALARIA VACCINE MARKET SIZE, BY TWO DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS MALARIA VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS MALARIA VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2018-2024 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY MRNA VACCINE, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY VIRAL VECTOR VACCINE, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY PUBLIC IMMUNIZATION PROGRAMS, 2025-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 330. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY CHILD, 2018-2024 (USD MILLION)
  • TABLE 332. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY CHILD, 2025-2032 (USD MILLION)
  • TABLE 333. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2018-2024 (USD MILLION)
  • TABLE 334. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY DOSAGE SCHEDULE, 2025-2032 (USD MILLION)
  • TABLE 335. GLOBAL MALARIA VACCINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 336. GLOBAL MALARIA VACCINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 337. ASEAN MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 338. ASEAN MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 339. ASEAN MALARIA VACCINE MARKET SIZE, BY VACCINE TYPE,